From: Immunotherapy in head and neck cancer: aiming at EXTREME precision
Trial, ClinicalTrials.gov identifier | Phase | Estimated enrolment | Immunotherapeutic approach | Regimen (treatment arms A, B, C) | Primary completion date |
---|---|---|---|---|---|
NCT01836029 (ACTIVE8) | IIR | 175 | TLR8 agonist |
A: Motolimodc + PFE B: Placebo + PFE | 9/2016 |
NCT02823574 (CheckMate-714) | IIR | 315 |
Anti-PD-1 Anti-CTLA-4 |
A: Nivolumabc + ipilimumabc
B: Nivolumabc + placebo | 2/2018 |
NCT02551159 (KESTREL) | III | 760 |
Anti-PD-L1 Anti-CTLA-4 |
A: Durvalumabc
B: Durvalumabc + tremelimumabc C: PFE | 3/2018 |
NCT02358031 (KEYNOTE-048) | III | 825 | Anti-PD-1 |
A: Pembrolizumabc
B: Pembrolizumabc + PF C: PFE | 3/2018 |
NCT02578641b | III | 330 | Autologous EBV-specific CTLs |
A: CTLsc + gemcitabine + carboplatin B: Gemcitabine + carboplatin | 12/2018 |
NCT02624999 | IIR | 100 | Vaccine |
A: AlloVax™ c, d
B: Cisplatin | 12/2018 |
NCT02741570 (CheckMate-651) | III | 490 |
Anti-PD-1 Anti-CTLA-4 |
A: Nivolumabc + ipilimumabc
B: PFE | 1/2019 |